Who are Oxymetazoline gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmedetomidine 0.5 microgram/kg, fentanyl and dexmedetomindine, dexmedetomidine (IN), Mirtazapine Tablets, ketamine- dexmeditomidine admixure, oxymetazoline-fluticasone propionate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxymetazoline-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Oxymetazoline gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxymetazoline gel (Oxymetazoline gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Dermatology / Otolaryngology.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Dermatology / Otolaryngology Small molecule Live · refreshed every 30 min

Target snapshot

Oxymetazoline gel (Oxymetazoline gel) — RDD Pharma Ltd. Oxymetazoline is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of blood vessels in the nasal mucosa and skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxymetazoline gel TARGET	Oxymetazoline gel	RDD Pharma Ltd	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 0.5 microgram/kg	Dexmedetomidine 0.5 microgram/kg	Sindh Institute of Urology and Transplantation	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
fentanyl and dexmedetomindine	fentanyl and dexmedetomindine	The Affiliated Hospital of Qingdao University	marketed	Opioid agonist combined with alpha-2 adrenergic agonist	Mu opioid receptor (fentanyl); Alpha-2 adrenergic receptor (dexmedetomidine)
dexmedetomidine (IN)	dexmedetomidine (IN)	Azienda Ospedaliera di Padova	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Mirtazapine Tablets	Mirtazapine Tablets	National Institute of Mental Health, Dhaka	marketed	Tetracyclic antidepressant	Alpha-2 adrenergic receptor, 5-HT2 receptor, 5-HT3 receptor
ketamine- dexmeditomidine admixure	ketamine- dexmeditomidine admixure	Kasr El Aini Hospital	marketed	Dissociative anesthetic with alpha-2 adrenergic agonist	NMDA receptor (ketamine); alpha-2 adrenergic receptor (dexmedetomidine)
oxymetazoline-fluticasone propionate	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxymetazoline gel — Competitive Intelligence Brief. https://druglandscape.com/ci/oxymetazoline-gel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing